Default option nudge may boost cancer screening in High-Risk groups
NCT ID NCT07682220
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial tests whether presenting a cancer screening appointment as a pre-selected default option (opt-out) makes people at high risk for lung or stomach cancer more likely to accept it, compared to a standard opt-in approach. Participants complete an online questionnaire and decide about a simulated screening appointment. The study also examines how people feel about being nudged once the tactic is disclosed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Default option nudge (behavioral intervention)
What this could lead to
If effective, this simple scheduling change could boost cancer screening rates in high-risk populations, potentially catching more cancers early.
What could go wrong
This is a simulated online study, not real screening. Real-world behavior may differ, and some people may react negatively to being nudged.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- LungVision AI Navigation for Lung Nodule Surgery NCT07682012
- EP0057 + Olaparib for Lung, Bladder, Prostate Ca NCT02769962
- Liquid Biopsy in NSCLC: NCT04566432
- AI-ROSE for Lung Cancer Diagnosis Trial (NCT07662967)
- One-Click Autofocus vs Manual Focus in Endoscopy NCT07664813
- AI Predicts Lung Nodule Growth from CT Scans – NCT07647692
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbin Medical University
Harbin, Heilongjiang, 150081, China